Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 350 participants.
Also called NCT01798706
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 350 participants
- Sponsor
- Registry
-
NCT01798706 -
2012-003292-19
-
- Main results
- Lixisenatide Therapy in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Antidiabetic Treatment: The GetGoal-O Randomized Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Bulgaria, Canada, Denmark, Germany, Norway, Peru, Poland, South Africa, Spain, Sweden, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01798706. Randomized; quadruple masking; primary purpose treatment. Start 2013-06 (registry gives no type); primary completion 2015-02 (actual). Results posted on 2016-10-14.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients
- Acronym
- GetGoal-O
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Lixisenatide (AVE0010)
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Antidiabetic background therapy
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct01798706- Content hash
0e2229039a86174f928e24f443eb1b1d325b48711673f91e0a31376548465d2f